Cancer Subclonal Genetic Architecture as a Key to Personalized Medicine
The future of personalized oncological therapy will likely rely on evidence-based medicine to integrate all of the available evidence to delineate the most efficacious treatment option for the patient. To undertake evidence-based medicine through use of targeted therapy regimens, identification of t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2013-12-01
|
| Series: | Neoplasia: An International Journal for Oncology Research |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558613800103 |
| _version_ | 1811283288945328128 |
|---|---|
| author | Alnawaz Rehemtulla |
| author_facet | Alnawaz Rehemtulla |
| author_sort | Alnawaz Rehemtulla |
| collection | DOAJ |
| description | The future of personalized oncological therapy will likely rely on evidence-based medicine to integrate all of the available evidence to delineate the most efficacious treatment option for the patient. To undertake evidence-based medicine through use of targeted therapy regimens, identification of the specific underlying causative mutation(s) driving growth and progression of a patient's tumor is imperative. Although molecular subtyping is important for planning and treatment, intraclonal genetic diversity has been recently highlighted as having significant implications for biopsy-based prognosis. Overall, delineation of the clonal architecture of a patient's cancer and how this will impact on the selection of the most efficacious therapy remain a topic of intense interest. |
| first_indexed | 2024-04-13T02:08:45Z |
| format | Article |
| id | doaj.art-dcdb379f1121449081a1efcde906af9a |
| institution | Directory Open Access Journal |
| issn | 1476-5586 1522-8002 |
| language | English |
| last_indexed | 2024-04-13T02:08:45Z |
| publishDate | 2013-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neoplasia: An International Journal for Oncology Research |
| spelling | doaj.art-dcdb379f1121449081a1efcde906af9a2022-12-22T03:07:22ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022013-12-0115121410142010.1593/neo.131972Cancer Subclonal Genetic Architecture as a Key to Personalized MedicineAlnawaz RehemtullaThe future of personalized oncological therapy will likely rely on evidence-based medicine to integrate all of the available evidence to delineate the most efficacious treatment option for the patient. To undertake evidence-based medicine through use of targeted therapy regimens, identification of the specific underlying causative mutation(s) driving growth and progression of a patient's tumor is imperative. Although molecular subtyping is important for planning and treatment, intraclonal genetic diversity has been recently highlighted as having significant implications for biopsy-based prognosis. Overall, delineation of the clonal architecture of a patient's cancer and how this will impact on the selection of the most efficacious therapy remain a topic of intense interest.http://www.sciencedirect.com/science/article/pii/S1476558613800103 |
| spellingShingle | Alnawaz Rehemtulla Cancer Subclonal Genetic Architecture as a Key to Personalized Medicine Neoplasia: An International Journal for Oncology Research |
| title | Cancer Subclonal Genetic Architecture as a Key to Personalized Medicine |
| title_full | Cancer Subclonal Genetic Architecture as a Key to Personalized Medicine |
| title_fullStr | Cancer Subclonal Genetic Architecture as a Key to Personalized Medicine |
| title_full_unstemmed | Cancer Subclonal Genetic Architecture as a Key to Personalized Medicine |
| title_short | Cancer Subclonal Genetic Architecture as a Key to Personalized Medicine |
| title_sort | cancer subclonal genetic architecture as a key to personalized medicine |
| url | http://www.sciencedirect.com/science/article/pii/S1476558613800103 |
| work_keys_str_mv | AT alnawazrehemtulla cancersubclonalgeneticarchitectureasakeytopersonalizedmedicine |